[Acute leukemia. Case material and therapeutic results]

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Context:

• This study analyzes treatment outcomes for adult acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients between 1969-1973.
• It investigates remission rates, duration, and survival times across different leukemia subtypes and treatment regimens.
• The research focuses on the efficacy of induction therapy and maintenance chemotherapy, specifically cyclic chemotherapy.

Purpose:

• To evaluate the effectiveness of various treatment strategies for adult ALL and AML.
• To determine factors influencing remission and survival, including leukemia subtype, patient age, and initial leukocyte count.
• To compare the impact of different chemotherapy protocols on treatment outcomes.

Summary:

• For ALL, a 61% complete remission rate was achieved, with cyclic chemotherapy proving superior for remission maintenance.
• AML subtypes showed varying remission rates (25-50%) and survival times; myelomonocytic leukemia yielded the best outcomes.
• Optimal remission rates were observed in patients with initial leukocyte counts between 10,000-50,000/mm³, and cyclic chemotherapy adherence improved results, except for stem cell leukemia.

Impact:

• Highlights the importance of cyclic chemotherapy in maintaining remission for adult leukemia patients.
• Provides valuable data on prognostic factors and subtype-specific outcomes in ALL and AML.
• Informs clinical decision-making for leukemia treatment protocols and patient management strategies.